Towards a nanospecific approach for risk assessment.
暂无分享,去创建一个
Adriele Prina-Mello | Maria João Silva | Agnes G Oomen | Flemming R Cassee | Christian Micheletti | Joan Cabellos | Socorro Vázquez-Campos | Gemma Janer | Fabrice Nesslany | Rob J Vandebriel | Susan Dekkers | Eric A J Bleeker | Natalia Fuentes | Teresa Borges | Dania Movia | Ana R Ribeiro | Paulo Emílio Leite | Monique Groenewold | Adrienne J A M Sips | Aart Dijkzeul | Tom van Teunenbroek | Susan W P Wijnhoven | M. J. Silva | F. Cassee | R. Vandebriel | G. Janer | S. Vázquez-Campos | T. Borges | A. Prina‐Mello | F. Nesslany | A. Oomen | A. Sips | C. Micheletti | S. Wijnhoven | S. Dekkers | D. Movia | M. Groenewold | E. Bleeker | A. Ribeiro | P. E. Leite | J. Cabellos | T. van Teunenbroek | N. Fuentes | A. Dijkzeul | Dania Movia | M. Silva
[1] Warren H. Finlay,et al. Particle deposition in the respiratory tract , 2019, The Mechanics of Inhaled Pharmaceutical Aerosols.
[2] A. Burls. Critical appraisal , 2016, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.
[3] Ana Proykova,et al. Scientific Committee on Emerging and Newly Identified Health Risks SCENIHR Opinion on the Guidance on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices , 2015 .
[4] Ken Donaldson,et al. Possible genotoxic mechanisms of nanoparticles: Criteria for improved test strategies , 2010, Nanotoxicology.
[5] Craig A. Poland,et al. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma , 2010, Particle and Fibre Toxicology.
[6] Reinhard Kreiling,et al. A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). , 2015, Regulatory toxicology and pharmacology : RTP.
[7] Gibson Peter,et al. Towards a review of the EC Recommendation for a definition of the term "nanomaterial": Part 3: Scientific-technical evaluation of options to clarify the definition and to facilitate its implementation , 2015 .
[8] P. Hoet,et al. Nanoparticles – known and unknown health risks , 2004, Journal of nanobiotechnology.
[9] Andreas Luch,et al. A redox proteomics approach to investigate the mode of action of nanomaterials. , 2016, Toxicology and applied pharmacology.
[10] Xiang Wang,et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. , 2013, Accounts of chemical research.
[11] Gibson Peter,et al. Towards a review of the EC Recommendation for a definition of the term "nanomaterial"; Part 1: Compilation of information concerning the experience with the definition , 2014 .
[12] Maria João Silva,et al. Role of Nanogenotoxicology Studies in Safety Evaluation of Nanomaterials , 2015 .
[13] Gibson Peter,et al. Towards a review of the EC Recommendation for a definition of the term "nanomaterial"Part 2: Assessment of collected information concerning the experience with the defintion , 2014 .
[14] R. Tice,et al. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing , 2000, Environmental and molecular mutagenesis.
[15] Rui Chen,et al. Beyond PM2.5: The role of ultrafine particles on adverse health effects of air pollution. , 2016, Biochimica et biophysica acta.
[16] Eleonore Fröhlich,et al. Cellular targets and mechanisms in the cytotoxic action of non-biodegradable engineered nanoparticles. , 2013, Current drug metabolism.
[17] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[18] A. Collins,et al. The comet assay for DNA damage and repair , 2004, Molecular biotechnology.
[19] Peter Wick,et al. Engineered nanomaterial uptake and tissue distribution: from cell to organism , 2013, International journal of nanomedicine.
[20] Jingwen Chen,et al. A practical approach to determine dose metrics for nanomaterials , 2015, Environmental toxicology and chemistry.
[21] Dhimiter Bello,et al. Mapping the biological oxidative damage of engineered nanomaterials. , 2013, Small.
[22] Jim E Riviere,et al. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice , 2015, Nanotoxicology.
[23] Marina A Dobrovolskaia,et al. Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.
[24] G. Oberdörster,et al. Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.
[25] Lang Tran,et al. ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy , 2014, Particle and Fibre Toxicology.
[26] Marina A Dobrovolskaia,et al. Current understanding of interactions between nanoparticles and the immune system. , 2016, Toxicology and applied pharmacology.
[27] Henriqueta Louro,et al. Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells , 2005, Environmental and molecular mutagenesis.
[28] Julie Laloy,et al. Suitability of analytical methods to measure solubility for the purpose of nanoregulation , 2015, Nanotoxicology.
[29] Paul L. Carmichael,et al. Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs , 2011, Mutagenesis.
[30] Min Chen,et al. Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. , 2005, Experimental cell research.
[31] Antonio Marcomini,et al. Supporting decision-making for sustainable nanotechnology , 2015, Environment Systems and Decisions.
[32] M. Marinovich,et al. Risk Assessment of Products of Nanotechnologies , 2009 .
[33] J. Powell,et al. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. , 2010, Journal of autoimmunity.
[34] Lang Tran,et al. Safe handling of nanotechnology , 2006, Nature.
[35] Teresa F. Fernandes,et al. The MARINA Risk Assessment Strategy: A Flexible Strategy for Efficient Information Collection and Risk Assessment of Nanomaterials , 2015, International journal of environmental research and public health.
[36] Kimberly F. Sellers,et al. Grouping nanomaterials : A strategy towards grouping and read-across , 2015 .
[37] Jim E Riviere,et al. Pharmacokinetics of metallic nanoparticles. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[38] Hugh J. Byrne,et al. Concern-driven integrated approaches to nanomaterial testing and assessment – report of the NanoSafety Cluster Working Group 10 , 2013, Nanotoxicology.
[39] Reinhard Kreiling,et al. A critical appraisal of existing concepts for the grouping of nanomaterials. , 2014, Regulatory toxicology and pharmacology : RTP.
[40] Steffen Loft,et al. Nanomaterial translocation–the biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs–a review , 2015, Critical reviews in toxicology.
[41] M. Fenech. The in vitro micronucleus technique. , 2000, Mutation research.
[42] Craig A. Poland,et al. Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[43] Antonio Marcomini,et al. Grouping and Read-Across Approaches for Risk Assessment of Nanomaterials , 2015, International journal of environmental research and public health.
[44] S. Doak,et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. , 2009, Biomaterials.
[45] W. D. de Jong,et al. Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food , 2015, Nanotoxicology.
[46] F. Goñi-de-Cerio,et al. Nanoparticles and blood-brain barrier: the key to central nervous system diseases. , 2014, Journal of nanoscience and nanotechnology.
[47] Jeroen Lammertyn,et al. Semi-automatic size measurement of primary particles in aggregated nanomaterials by transmission electron microscopy , 2014 .
[48] Reinhard Kreiling,et al. Case studies putting the decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping) into practice. , 2016, Regulatory toxicology and pharmacology : RTP.
[49] Claudia Röhl,et al. Manufactured nanomaterials: categorization and approaches to hazard assessment , 2014, Archives of Toxicology.
[50] I Pastan. Cell transformation. , 1979, Methods in enzymology.
[51] Konrad Hungerbühler,et al. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles , 2013, International journal of nanomedicine.
[52] Gibson Peter,et al. Requirements on measurements for the implementation of the European Commission definition of the term 'nanomaterial' , 2012 .
[53] Lutz Mädler,et al. Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. , 2012, ACS nano.
[54] Wijnhoven Swp,et al. Exposure to nanomaterials in consumer products , 2009 .
[55] Manuela Semmler-Behnke,et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration , 2011, Nanotoxicology.
[56] Craig A. Poland,et al. Nanotoxicity: challenging the myth of nano-specific toxicity. , 2013, Current opinion in biotechnology.
[57] Karen L Wooley,et al. Cytokines as biomarkers of nanoparticle immunotoxicity. , 2013, Chemical Society reviews.